Articles related to ASCO
ASCO GU 2024: Advances in Prostate Cancer
Recent studies highlight the potential of cabozantinib plus atezolizumab in improving progression-free survival for mCRPC patients and confirm the benefits of high-dose radiotherapy in high-risk prostate cancer treatment, offering new insights into personalized care strategies.
Oncology, Medical February 20th 2024
ASCO GI 2024: Data May Change Practice in HCC
Recent findings from the ASCO Gastrointestinal Cancers Symposium 2024 underscore the potential of innovative therapeutic combinations in enhancing outcomes for hepatocellular carcinoma patients, particularly those with unresectable or high-risk disease.
Oncology, Medical February 12th 2024
A Tale of Two ICIs: Adjuvant Pembro Ups Survival in RCC, Nivo Doesn’t
Pembrolizumab now represents a transformative advancement in the adjuvant treatment of clear cell renal cell carcinoma, significantly reducing the risk of progression or death by 38% compared to placebo.
Oncology, Medical February 5th 2024